Marshall Wace
SABS icon

Marshall Wace’s SAB Biotherapeutics SABS Stock Holding History

Marshall Wace’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-463,925
Closed -$1.78M – 3658
2026
Q1 		$1.78M Buy
463,925
+227,465
+96% +$907K ﹤0.01% 1852
2025
Q4 		$884K Buy
+236,460
New +$778K ﹤0.01% 1997
2025
Q1 		– Sell
-459,168
Closed -$1.75M – 3033
2024
Q4 		$1.75M Hold
459,168
– – ﹤0.01% 1500
2024
Q3 		$1.24M Hold
459,168
– – ﹤0.01% 1560
2024
Q2 		$1.42M Hold
459,168
– – ﹤0.01% 1526
2024
Q1 		$2.08M Buy
459,168
+640
+0.1% +$3.52K ﹤0.01% 1348
2023
Q4 		$3.16M Buy
+458,528
New +$3.84M 0.01% 1064
2022
Q1 		– Sell
-50
Closed -$3K – 3928
2021
Q4 		$3K Buy
+50
New +$4.69K ﹤0.01% 3778

Other funds holding SABS

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Marshall Wace's SABS Position: Q2 2026 in Review

Marshall Wace sold out of SAB Biotherapeutics (SABS) in Q2 2026, closing a stake of 463,925 shares — an estimated $1.78M sold.

Marshall Wace first reported a position in SABS in Q4 2021 and held it in 8 quarters. The position peaked at $3.16M in Q4 2023. 87 funds tracked by Wall St. Rank hold SABS as of Q2 2026.

  • Marshall Wace reported no remaining SAB Biotherapeutics position as of Q2 2026 after selling out during the quarter.
  • Marshall Wace sold 463,925 SAB Biotherapeutics shares in Q2 2026, an estimated $1.78M.
  • Marshall Wace first reported a position in SAB Biotherapeutics in Q4 2021 and held it in 8 quarters.
  • Marshall Wace's SAB Biotherapeutics position peaked at $3.16M in Q4 2023.
  • 87 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.